Severe Bleeding due to Cytomegalovirus Esophagitis in a Patient with Diabetes after Interbody Fusion Surgery

Shumpei Yamamoto¹,², Masaya Iwamuro¹, Muneaki Miyake², Naoyuki Nishimura², Motowo Mizuno³ and Hiroyuki Okada¹

Abstract:
A 49-year-old man with diabetes taking clopidogrel and celecoxib underwent interbody fusion surgery for spinal spondylolysis. Ten days after the surgery, he vomited a large amount of fresh blood. A blood examination revealed hemodynamic failure. Esophagogastroduodenoscopy showed an adherent blood clot and multiple superficial ulcers in the esophagus. Endoscopic hemostasis was successfully achieved. Biopsy specimens from the esophageal ulcer showed positive immunohistochemical staining results for anti-CMV antibodies. The esophageal ulcer improved after the oral administration of ganciclovir. This case emphasizes that CMV esophagitis with bleeding can occur in a diabetic patient with a poor nutritional status due to relative immune dysfunction.

Key words: cytomegalovirus esophagitis, diabetes, esophagogastroduodenoscopy, hypoalbuminemia

Introduction
Cytomegalovirus (CMV) can sometimes affect the gastrointestinal (GI) tract, and the majority of such CMV infections have been reported in immunosuppressed patients (1, 2). The colorectum is the most frequently affected site in the GI tract. In contrast, CMV esophagitis is relatively infrequent (2, 3). The symptoms of CMV esophagitis include dysphagia, odynophagia, and epigastric pain, while massive bleeding followed by hypovolemic shock is rarely observed.

We herein report a patient with CMV esophagitis who presented with hematemesis after orthopedic surgery. In addition, the patient presented with hematemesis and hemodynamic failure due to CMV esophagitis. It is noteworthy that the patient did not show apparent immunosuppression, although diabetes and hypoalbuminemia might lead to relative immune dysfunction. This case underscores the fact that CMV esophagitis can occur in a diabetic patient with a poor nutritional status and cause massive bleeding.

Case Report
A 49-year-old man was referred to Kurashiki Central Hospital owing to chronic back pain and paresthesia caused by spondylolysis, lasting for several years. He had a history of diabetes and cerebral infarction. He had been taking clopidogrel, cyclooxygenase-2 inhibitor celecoxib, and oral hypoglycemic agents (i.e. metformin, empagliflozin, and sitagliptin). Preoperative testing was negative for human immunodeficiency virus.

He underwent interbody fusion surgery for the treatment of S4 spondylolysis. Since his diabetic condition was uncontrolled, his HbA1c value was 9.0%. He had undergone intensive insulin therapy for four weeks prior to the surgery that had gradually improved his blood sugar level; however, the value had remained at 8.4%. There was no diabetic nephropathy or retinopathy. After the surgery, his white blood cell (WBC) count and C-reactive protein (CRP) level temporarily increased, and the serum albumin level decreased rapidly (Table 1). We hypothesized that the systemic response to surgical injury to the spine had led to the in-
Table 1.

|       | Pre 7 | POD2 | POD5 | POD7 | POD10 | POD13 | POD15 | POD35 |
|-------|-------|------|------|------|-------|-------|-------|-------|
| Hb g/dL | 15.9 | 17.4 | 14.1 | 13.5 | 11.9  | 8.1   | 8.6   | 12    |
| Alb g/dL | 4.1  | 3.8  | 2.5  | 2.5  | 2.7   | 2.6   | 2.8   | 4.1   |
| BUN mg/dL | 13   | 26   | 17   | 10   | 20    | 6     | 4     | 14    |
| Cr mg/dL | 0.57 | 0.73 | 0.44 | 0.46 | 0.62  | 0.55  | 0.61  | 0.63  |
| WBC /μL | 7,000 | 27,800 | 13,100 | 11,800 | 9,100 | 7,700 | 6,800 | 7,600 |
| CRP mg/dL | 0.09 | 22.51 | 5.76  | 3.73  | 2.3   | 0.57  | 0.39  | 0.06  |
| FBS mg/dL | -   | 306  | 148  | 212  | 166   | 163   | 145   | -     |

Pre: preoperative day, POD: postoperative day, Hb: hemoglobin, Alb: albumin, BUN: blood urea nitrogen, Cr: creatinine, WBC: white blood cell count, CRP: C-reactive protein, FBS: fasting blood sugar

Figure 1. (a, b) An adherent blood clot occupying the esophagus and multiple superficial ulcers affecting the entire circumference of the upper to distal esophagus; (c) multiple superficial ulcers in the duodenum.

Discussion

CMV is a species of the herpes virus and a common viral pathogen in humans. Serious infectious complications are induced either by reactivation of a latent CMV infection or by the acquisition of a primary CMV infection (4). Reactivation of CMV mainly occurs in immunosuppressed patients with various underlying diseases, such as concomitant immunodeficiency virus infection, transplant recipients who are taking immunosuppressive agents, those with malignant diseases...
and inflammatory bowel diseases, and patients undergoing chemotherapy or steroid treatment. Serious manifestations owing to CMV infection sometimes result in severe morbidity and mortality in affected patients (1, 4).

CMV infection is generally infrequent in immunocompetent patients. However, the numbers of case reports and case series describing CMV infection in immunocompetent patients have been increasing. Susana et al. reported that 25% (3/12) of patients with CMV infection in the GI tract were not immunodeficient or under immunosuppression treatment (5). Bonetti et al. reported that 50% (15/30) of the patients were apparently healthy individuals (6). We presumed that the patient in the present case was not severely immunosuppressed; however, we could not confirm this be-

Figure 2. (a) A red exposed vessel with oozing hemorrhaging; (b) hemostasis of the exposed vessel was successfully achieved using hemoclips.

Figure 3. (a) Multiple incompletely healed ulcers in the esophagus; (b) incompletely healed ulcer in the duodenum.

Figure 4. Histological findings of biopsy specimens. (a) Intranuclear inclusion bodies in Hematoxylin and Eosin staining (arrow); (b) immunohistochemical staining showing cells positive for anti-CMV antibodies (arrow).
cause we did not measure the CD4 and CD8 expression. Furthermore, uncontrolled diabetes and hypoalbuminemia might have caused immune dysfunction to some degree, leading to CMV infection in the esophagus. Some reports have indicated an association between CMV infection and diabetes mellitus (7-9). Lantini et al. noted that severe manifestations with CMV infection in an immunocompetent patient were partly associated with immune dysfunction, such as that observed in kidney disease or diabetes mellitus (7). Lee et al. reviewed reactivated CMV proctitis in an immunocompetent patient and reported that 54.5% (6/11) of patients with CMV proctitis had diabetes mellitus (9). The possible mechanisms underlying susceptibility to CMV in diabetes patients include hyperglycemia that causes damage to the neutrophil function, reduction of response to T cells, and dysfunction of humoral immunity (10). Previous studies regarding cell-mediated immunity reported that the T cell function was defective in poorly controlled type 1 diabetes patients (11). The complement system is associated with humoral immunity, and some studies have revealed a deficiency in the C4 component in diabetes (12). These deficiencies cause polymorphonuclear dysfunction and reduce the cytokine response. The B cell humoral immune response function is also affected by complement activation products. In addition, previous reports mentioned the association between hypoalbuminemia and CMV infection. Hypoalbuminemia revealed itself to be a significant risk factor for CMV infection in rheumatic disease and chronic lymphoproliferative diseases, such as in liver transplant recipients (13-15). Furthermore, Van et al. observed a decrease of CMV-specific immunoglobulin G and albumin levels in patients with CMV reactivation after renal transplantation (16). These findings indicate that CMV infection should be considered in the differential diagnosis, not only in apparently immunosuppressed patients but also in patients with relative immune dysfunction, such as those with diabetes and/or hypoalbuminemia.

Although the colorectum is the most common site of CMV infection in the GI tract, involvement of the upper GI tract, which leads to esophagitis, gastritis, duodenitis, gastric ulcer, or duodenal ulcer, has also been reported (3). The most common symptoms associated with CMV esophagitis are dysphagia, odynophagia, and epigastric pain (17). Hematemesis is a rare manifestation of CMV esophagitis, compared with CMV gastritis/duodenitis (18, 19). Hence, there have been few reports describing patients with CMV esophagitis who presented with hematemesis and/or hemodynamic failure.

To our knowledge, seven patients with CMV esophagitis showing hematemesis have been reported in the literature (Table 2) (5, 19-24). Five of the seven patients were under immunosuppression treatment and had been taking immunosuppressive agents such as steroids or cyclophosphamide. None of the patients had diabetes mellitus or hypoalbuminemia as far as we have searched. Among the seven patients, only three showed hemodynamic failure; all of them were immunosuppressed and had been taking immunosuppressive agents. Two patients required insertion of a Sengstaken-Blakemore tube, because the bleeding source could not be identified and the bleeding was uncontrollable. In the patient in the present case, although hemostasis was successfully achieved, it was difficult to detect the site of bleeding. In one patient in a previous study, a red exposed vessel was endoscopically treated using hemoclip (24), as in our case.

Representative endoscopic features of CMV infection in the upper GI tract include deep, punched-out ulcers. However, endoscopic features of previously reported CMV esophagitis are often nonspecific, including solitary or multiple deep ulcers and superficial ulcers, as shown in Table 2. The present patient also showed multiple superficial ulcers affecting the entire circumference of the upper to distal esophagus, which necessitated a differential diagnosis from other diseases, such as acute esophageal mucosal lesion, acute esophageal necrosis (AEN), and non-steroidal anti-inflammatory drug-induced ulcer (25, 26). In fact, this patient had been taking clopidogrel and celecoxib, which can also cause mucosal disorders and severe bleeding (27, 28). There has been only one case report describing AEN with CMV infection after renal transplantation (29). Although the pathogenesis of AEN remains unclear, it is considered that the temporary reduction of esophageal blood perfusion and acid reflux cause AEN. In the present case, we considered CMV infection to be the principal cause of esophagitis, as the esophageal ulcers were improved after the administration.
| author | endoscopic features/disease location | clinical presentation | treatment | Hemodynamic failure | DIC | Immune-compromised state | comorbidity | Immuno-suppressive agents | antithrombotic drug/NSAIDs | diagnosis | treatment | outcome |
|--------|-----------------------------------|-----------------------|-----------|-------------------|-----|------------------------|------------|------------------------|--------------------------|-----------|-----------|--------|
| Marques (5) | deep ulcer/unknown | unknown | no | no | AIDs, DLBCL | Immuno-suppressive agents | unknown | intranuclear inclusions or immunostaining | GCV +VGCV | alive |
| Featherstone (13) | multiple ulcer/middle esophagus | hematemesis | S-B tube → operation | yes | yes | GPA, achalasia | PSL | no | surgical specimen: intranuclear inclusions /immunostaining | GCV | alive |
| Ozaki (14) | superficial ulcer/unknown | hematemesis | epinephrine /thrombin | yes | no | SLE | PSL, cyclophosphamide | unknown | biopsy: immunostaining | GCV | alive |
| Yagain (15) | blackish discoloration/unknown | hematemesis | none | no | no | alcoholism | none | no | biopsy: intranuclear inclusions | none | alive |
| Venkataranani (16) | superficial ulcer/unknown | hematemesis | unknown | no | no | no | acute pancreatitis following ERCP | none | no | biopsy: immunostaining | GCV | death (pancreatitis) |
| Mayeux (17) | severe ulcer/lower esophagus | hematemesis | S-B tube | no | yes | endstage renal failure | liver cirrhosis | PSL | no | autopsy: intranuclear inclusions | none | death (DIC) |
| Kanda (18) | superficial ulcer/middle esophagus | hematemesis | clipping | yes | no | MPA | PSL, cyclophosphamide | no | biopsy: intranuclear inclusions /immunostaining | GCV | death (pneumonia) |

GPA: granulomatosis with polyangiitis, MPA: microscopic polyangiitis, SLE: systemic lupus erythematosus, AIDs: acquired immunodeficiency syndrome, DLBCL: diffuse large B-cell lymphoma, PSL: prednisolone, GCV: ganciclovir, VGCV: valganciclovir, S-B tube: Sengstaken-Blakemore tube, DIC: disseminated intravascular coagulation, NSAIDs: non-steroidal anti-inflammatory drug.
of the anti-CMV drug. However, it is quite possible that other factors contributed to the pathogenesis of the esophageal ulcer, such as hyperglycemia, hypovolemia, hypoalbuminemia, acid reflux, antiplatelet drugs, and NSAIDs.

The gold standard for the diagnosis of CMV infection in the GI tract is a histopathology analysis with immunohistochemical staining (30). The current patient and all previously reported patients, except for one, were diagnosed based on the results of histopathological examinations. However, histology has a low sensitivity, so CMV infection may be missed (31). In the present patient, although CMV was not detected in the duodenum, the duodenal ulcer might have been caused by a CMV infection as well, as it presented with a punched-out ulcer (Fig. 4C).

Anti-CMV drugs, such as ganciclovir and valganciclovir, were used in all cases. Lim et al. suggested that these drugs were important for preventing rebleeding from CMV-related lesions in the GI tract (32). Three of the seven patients died after bleeding due to disseminated intravascular coagulation, pneumonia, and/or progressive complications of pancreatitis. Although this lethal outcome was more likely to be associated with their immunosuppressed condition than with CMV esophagitis, the bleeding event obviously worsened their condition.

In conclusion, CMV esophagitis can occur not only in immunosuppressed patients but also in those with relative immune dysfunction caused by diabetes and hypoalbuminemia. Furthermore, although rare, CMV may cause massive bleeding, leading to hemodynamic failure. Physicians should therefore consider CMV esophagitis in the differential diagnosis of esophageal bleeding of unknown cause, even in patients without apparent immunodeficiency. A prompt histopathological diagnosis and administration of anti-CMV drugs are essential for management of CMV esophagitis.

The authors state that they have no Conflict of Interest (COI).

References

1. Griffiths PD. Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation. Lancet Infect Dis 12: 790-798, 2012.
2. Maiorana A, Baccarini P, Foroni M, Bellini N, Giusti F. Human cytomegalovirus infection of the gastrointestinal tract in apparently immunocompetent patients. Hum Pathol 34: 1331-1336, 2003.
3. Iwamuro M, Kondo E, Tanaka T; et al. Endoscopic Manifestations and Clinical Characteristics of Cytomegalovirus Infection in the Upper Gastrointestinal Tract. Acta Med Okayama 71: 97-104, 2017.
4. Weile J, Streeck B, Muck J, et al. Severe cytomegalovirus-associated esophagitis in an immunocompetent patient after short-term steroid therapy. J Clin Microbiol 47: 3031-3033, 2009.
5. Marques S, Carmo J, Pinto D, Bispo M, Ramos S, Chagas C. Cytomegalovirus Disease of the Upper Gastrointestinal Tract: A 10-Year Retrospective Study. GE Port J Gastroenterol 24: 262-268, 2017.
6. Reggiani Bonetti L, Losi L, Di Gregorio C, et al. Cytomegalovirus infection of the upper gastrointestinal tract: a clinical and pathological study of 30 cases. Scand J Gastroenterol 46: 1228-1235, 2011.
7. Lancini D, Faddy HM, Flower R, Hogan C. Cytomegalovirus disease in immunocompetent adults. Med J Aust 201: 578-580, 2014.
8. Mendy A, Gasana J, Vieira ER, Diallo H. Prospective study of cytomegalovirus seropositivity and risk of mortality from diabetes. Acta Diabetol 51: 723-729, 2014.
9. Lee CY, Chen YH, Lu PL. Reactivated cytomegalovirus proctitis in an immunocompetent patient presenting as nosocomial diarrhea: a case report and literature review. BMC Infect Dis 17: 113, 2017.
10. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab 16 Suppl 1: S27-S36, 2012.
11. Peleg AY, Weeraratna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 23: 3-13, 2007.
12. Stocekle M, Kaech C, Trampuz A, Zimmerli W. The role of diabetes mellitus in patients with bloodstream infections. Swiss Med Wkly 138: 512-519, 2008.
13. Kim JM, Kim SJ, Joh JW; et al. The risk factors for cytomegalovirus syndrome and tissue-invasive cytomegalovirus disease in liver transplant recipients who have cytomegalovirus antigenemia. Transplant Proc 42: 890-894, 2010.
14. Borthakur G, Lin E, Faderl S, et al. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer 110: 2478-2483, 2007.
15. Kaneshita S, Kida T, Nagahara H, et al. The Difference in the Clinical Characteristics between Cytomegalovirus Disease and Asymptomatic Cytomegalovirus Reactivation in Rheumatic Diseases. Arthritis Rheumatol 69, 2017.
16. Van der Giessen M, van den Berg AP, van der Bij W, Postma S, van Son WJ, The TH. Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenemia and disease activity in kidney recipients with an active cytomegalovirus infection. Clin Exp Immunol 80: 56-61, 1990.
17. Wang HW, Kuo CJ, Lin WR, et al. The clinical characteristics and manifestations of cytomegalovirus esophagitis. Dis Esophagus 29: 392-399, 2016.
18. Peter A, Telkes G, Varga M, Sarvary E, Kovalszky J. Endoscopic diagnosis of cytomegalovirus infection of upper gastrointestinal tract in solid organ transplant recipients: Hungarian single-center experience. Clin Transplant 18: 580-584, 2004.
19. Featherstone RJ, Camero LG, Khatib R, Snower D, Mungara P. Massive esophageal bleeding in achalasia complicated by cytomegalovirus esophagitis. Ann Thorac Surg 59: 1021-1022, 1995.
20. Ozaki T, Yamashita H, Kaneko S, et al. Cytomegalovirus disease of the upper gastrointestinal tract in patients with rheumatic diseases: a case series and literature review. Clin Rheumatol 32: 1683-1690, 2013.
21. Yagain K, Rao L, Pai K, Pai G. Cytomegalovirus esophagitis in nonimmunocompromised patient—presenting as an acute necrotic (black) esophagitis. Indian J Pathol Microbiol 54: 852-853, 2011.
22. Venkataramani A, Schlueter AJ, Spech TJ, Greenberg E. Cytomegalovirus esophagitis in an immunocompetent host. Gastrointest endoscopy 40: 392-393, 1994.
23. Mayeux GP, Smith JW. Massive esophageal bleeding from cytomegalovirus esophagitis. The American journal of gastroenterology 85: 626, 1990.
24. Kanda K, Kume K, Yoshikawa I, et al. Cytomegalovirus esophagitis with massive upper-GI hemorrhage. Gastrointestinal endoscopy 59: 741-743, 2004.
25. Yasuda H, Yamada M, Endo Y, Inoue K, Yoshiba M. Acute necrotizing esophagitis: role of nonsteroidal anti-inflammatory drugs. Journal of gastroenterology 41: 193-197, 2006.
26. Xu XL, Zhu HH, Yin J. Esophageal ulcer induced by ibuprofen
tablets. Chronic Dis Transl Med 1: 245-246, 2015.

27. Chan FKL, Ching JYL, Tse YK, et al. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. The Lancet 389: 2375-2382, 2017.

28. Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. J Formos Med Assoc 111: 705-710, 2012.

29. Trappe R, Pohl H, Forberger A, Schindler R, Reinke P. Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection. Transpl Infect Dis 9: 42-45, 2007.

30. You DM, Johnson MD. Cytomegalovirus infection and the gastrointestinal tract. Curr Gastroenterol Rep 14: 334-342, 2012.

31. Goodman AL, Murray CD, Watkins J, Griffiths PD, Webster DP. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. Eur J Clin Microbiol Infect Dis 34: 13-18, 2015.

32. Lim LG, Rajnackova A, Yan B, Salto-Tellez M, Lim LL. Recurrent lower gastrointestinal bleeding secondary to cytomegalovirus-associated colonic ulcer in a non human immunodeficiency virus infected patient: timely diagnosis and treatment averted surgery. Colorectal Dis 11: 984-985, 2009.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).